20:22 , May 1, 2019 |  BC Extra  |  Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

MD Anderson findings could make radiation possible for pancreatic cancer  Researchers at University of Texas MD Anderson Cancer Center reported findings suggesting that HIF-PH inhibition could help prevent radiation-induced GI injury, the main factor that...
13:05 , Apr 25, 2019 |  BC Extra  |  Preclinical News

Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing. Samira Kiani, an ASU assistant professor who co-led the study, told...
19:31 , Mar 31, 2019 |  BC Extra  |  Clinical News

Neon data highlights epitope spread as key metric for neoantigen vaccines

Interim results from Neon's Phase Ib trial of NEO-PV-01 plus Opdivo nivolumab suggest proof of epitope spread will be a telling readout for neoantigen cancer vaccines. The data also point to tumor microenvironment-based predictors of...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
00:53 , Feb 1, 2019 |  BC Innovations  |  Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
13:07 , Jan 17, 2019 |  BC Innovations  |  Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
14:01 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

Neo opportunities in glioblastoma

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer. The study is...